RXi Pharmaceuticals Corporation Company Profile (NASDAQ:RXII)

About RXi Pharmaceuticals Corporation (NASDAQ:RXII)

RXi Pharmaceuticals Corporation logoRXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RXII
  • CUSIP: N/A
  • Web: www.rxipharma.com
Capitalization:
  • Market Cap: $12.2 million
  • Outstanding Shares: 23,247,000
Average Prices:
  • 50 Day Moving Avg: $0.56
  • 200 Day Moving Avg: $0.63
  • 52 Week Range: $0.49 - $2.93
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.90
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.26 per share
  • Price / Book: 2.02
Profitability:
  • EBIDTA: ($9,400,000.00)
  • Return on Equity: -155.48%
  • Return on Assets: -102.55%
Debt:
  • Current Ratio: 3.30%
  • Quick Ratio: 3.30%
Misc:
  • Average Volume: 243,947 shs.
  • Beta: 1.26
  • Short Ratio: 7.01
 

Frequently Asked Questions for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

What is RXi Pharmaceuticals Corporation's stock symbol?

RXi Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "RXII."

How were RXi Pharmaceuticals Corporation's earnings last quarter?

RXi Pharmaceuticals Corporation (NASDAQ:RXII) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.11). During the same period in the prior year, the company earned ($0.34) EPS. View RXi Pharmaceuticals Corporation's Earnings History.

When will RXi Pharmaceuticals Corporation make its next earnings announcement?

RXi Pharmaceuticals Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for RXi Pharmaceuticals Corporation.

Where is RXi Pharmaceuticals Corporation's stock going? Where will RXi Pharmaceuticals Corporation's stock price be in 2017?

0 brokerages have issued 12 month price objectives for RXi Pharmaceuticals Corporation's shares. Their predictions range from $1.71 to $1.71. On average, they expect RXi Pharmaceuticals Corporation's share price to reach $1.71 in the next twelve months. View Analyst Ratings for RXi Pharmaceuticals Corporation.

Who are some of RXi Pharmaceuticals Corporation's key competitors?

Who are RXi Pharmaceuticals Corporation's key executives?

RXi Pharmaceuticals Corporation's management team includes the folowing people:

  • Robert J. Bitterman, Independence Chairman of the Board
  • Geert Cauwenbergh Ph.D., President, Chief Executive Officer, acting Chief Financial Officer, Director
  • Gerrit Dispersyn, Chief Development Officer
  • Alexey Eliseev, Chief Business Officer
  • Keith L. Brownlie CPA, Independent Director
  • H. Paul Dorman, Independent Director
  • Jonathan Freeman Ph.D., Independent Director
  • Curtis A. Lockshin Ph.D., Independent Director

How do I buy RXi Pharmaceuticals Corporation stock?

Shares of RXi Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RXi Pharmaceuticals Corporation's stock price today?

One share of RXi Pharmaceuticals Corporation stock can currently be purchased for approximately $0.52.


MarketBeat Community Rating for RXi Pharmaceuticals Corporation (NASDAQ RXII)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for RXi Pharmaceuticals Corporation (NASDAQ:RXII) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $1.71 (232.04% upside)

Analysts' Ratings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2016S&P Equity ResearchLower Price Target$2.35 -> $1.71N/AView Rating Details
6/7/2016HC WainwrightInitiated CoverageBuy$3.50N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Earnings by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Earnings History by Quarter for RXi Pharmaceuticals Corporation (NASDAQ RXII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017N/AView Earnings Details
8/10/2017Q2 2017($0.11)($0.11)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.20)($0.12)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.23)($0.60)ViewN/AView Earnings Details
11/10/2016Q316($0.34)($0.34)ViewN/AView Earnings Details
8/11/2016Q216($0.36)($0.34)$0.01 millionViewListenView Earnings Details
5/13/2016Q116($0.45)($0.34)$34.00 million$10.00 millionViewListenView Earnings Details
3/30/2016Q415($0.05)($0.04)ViewListenView Earnings Details
11/12/2015Q315($0.04)($0.04)ViewListenView Earnings Details
8/12/2015Q215($0.09)($0.05)$0.02 millionViewListenView Earnings Details
5/13/2015Q115($0.10)($0.13)$0.02 million$0.03 millionViewListenView Earnings Details
3/30/2015Q414($0.14)($0.13)$0.02 million$0.01 millionViewN/AView Earnings Details
11/13/2014Q314($0.22)($0.17)$0.02 millionViewN/AView Earnings Details
8/14/2014Q214($0.25)($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.31)($0.32)$0.08 million$0.03 millionViewN/AView Earnings Details
3/28/2014($0.31)$0.84ViewN/AView Earnings Details
11/14/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
2017 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Insider Ownership Percentage: 5.71%
Institutional Ownership Percentage: 1.67%
Insider Trades by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Institutional Ownership by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Insider Trades by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Alexey EliseevInsiderSell176,800$0.54$95,472.00View SEC Filing  
9/1/2017Alexey EliseevInsiderSell23,200$0.57$13,224.00View SEC Filing  
8/24/2017Geert CauwenberghCEOBuy10,000$0.55$5,500.00View SEC Filing  
6/23/2017Gerrit DispersynInsiderBuy3,500$0.62$2,170.00View SEC Filing  
6/22/2017Geert CauwenberghCEOBuy10,000$0.63$6,300.00View SEC Filing  
4/26/2017Geert CauwenberghCEOBuy10,000$0.65$6,500.00View SEC Filing  
3/17/2017Geert CauwenberghCEOBuy10,000$0.77$7,700.00View SEC Filing  
2/17/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
2/8/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
1/25/2017Geert CauwenberghCEOBuy10,000$0.70$7,000.00View SEC Filing  
1/19/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
4/2/2015Geert CauwenberghCEOBuy5,000$0.72$3,600.00View SEC Filing  
2/17/2015Geert CauwenberghCEOBuy4,000$1.17$4,680.00View SEC Filing  
2/10/2015Geert CauwenberghCEOBuy2,000$1.24$2,480.00View SEC Filing  
1/22/2015Robert J BittermanDirectorBuy5,000$1.20$6,000.00View SEC Filing  
1/20/2015Geert CauwenberghCEOBuy10,000$1.03$10,300.00View SEC Filing  
12/30/2014Geert CauwenberghCEOBuy2,500$1.59$3,975.00View SEC Filing  
10/13/2014Geert CauwenberghCEOBuy3,000$1.68$5,040.00View SEC Filing  
9/19/2014Geert CauwenberghCEOBuy4,500$2.20$9,900.00View SEC Filing  
9/16/2014Geert CauwenberghCEOBuy5,000$2.08$10,400.00View SEC Filing  
9/15/2014Geert CauwenberghCEOBuy10,000$2.18$21,800.00View SEC Filing  
7/15/2014Geert CauwenberghCEOBuy1,000$2.50$2,500.00View SEC Filing  
7/9/2014Geert CauwenberghCEOBuy1,400$2.57$3,598.00View SEC Filing  
7/2/2014Geert CauwenberghCEOBuy2,000$2.86$5,720.00View SEC Filing  
6/19/2014Geert CauwenberghCEOBuy2,000$2.98$5,960.00View SEC Filing  
6/9/2014Geert CauwenberghCEOBuy1,000$3.05$3,050.00View SEC Filing  
6/4/2014Geert CauwenberghCEOBuy2,000$2.94$5,880.00View SEC Filing  
10/31/2013Geert CauwenberghCEOBuy1,000$3.17$3,170.00View SEC Filing  
10/23/2013Geert CauwenberghCEOBuy1,000$3.34$3,340.00View SEC Filing  
10/9/2013Geert CauwenberghCEOBuy1,000$3.15$3,150.00View SEC Filing  
8/29/2013Curtis LockshinDirectorBuy1,000$3.70$3,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Latest Headlines for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Source:
DateHeadline
americanbankingnews.com logo Analysts Anticipate RXi Pharmaceuticals Corporation (RXII) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - September 23 at 2:26 PM
finance.yahoo.com logoRXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference
finance.yahoo.com - September 19 at 7:21 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
finance.yahoo.com - September 19 at 7:20 AM
finance.yahoo.com logoFeatured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company
finance.yahoo.com - September 19 at 7:20 AM
streetinsider.com logoRXI Pharma (RXII) Reports Departure of Dr. Alexey Eliseev as Chief Business Officer
www.streetinsider.com - September 16 at 8:18 AM
finance.yahoo.com logoRXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer
finance.yahoo.com - September 16 at 8:17 AM
finance.yahoo.com logoBioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord Injury
finance.yahoo.com - September 15 at 8:31 AM
americanbankingnews.com logoInsider Selling: RXi Pharmaceuticals Corporation (RXII) Insider Sells 176,800 Shares of Stock
www.americanbankingnews.com - September 7 at 10:24 PM
streetinsider.com logoRXI Pharma (RXII) Reports Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts - StreetInsider.com
www.streetinsider.com - September 7 at 8:39 AM
finance.yahoo.com logoRXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
finance.yahoo.com - September 6 at 7:56 AM
finance.yahoo.com logoRXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
finance.yahoo.com - September 6 at 7:56 AM
americanbankingnews.com logoZacks: Brokerages Anticipate RXi Pharmaceuticals Corporation (RXII) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - September 4 at 8:18 PM
americanbankingnews.com logoRXi Pharmaceuticals Corp (RXII) Insider Alexey Eliseev Sells 23,200 Shares
www.americanbankingnews.com - September 1 at 10:24 PM
finance.yahoo.com logoRXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures Forum
finance.yahoo.com - August 31 at 9:37 AM
americanbankingnews.com logo Brokerages Expect RXi Pharmaceuticals Corporation (RXII) to Announce -$0.11 Earnings Per Share
www.americanbankingnews.com - August 17 at 8:18 AM
finance.yahoo.com logoEdited Transcript of RXII earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 12 at 7:34 AM
finance.yahoo.com logoInvestor Network: RXi Pharmaceuticals Corporation to Host Earnings Call
finance.yahoo.com - August 11 at 8:16 AM
americanbankingnews.com logoRXi Pharmaceuticals Corporation (RXII) Announces Earnings Results, Hits Expectations
www.americanbankingnews.com - August 10 at 11:29 PM
americanbankingnews.com logoFinancial Comparison: RXi Pharmaceuticals Corporation (NASDAQ:RXII) and Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - August 10 at 2:36 PM
rttnews.com logoEARNINGS SUMMARY: Details of RXi Pharmaceuticals Corp. Q2 Earnings Report
www.rttnews.com - August 10 at 7:33 AM
finance.yahoo.com logoRXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 10 at 7:33 AM
finance.yahoo.com logoRXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing
finance.yahoo.com - August 9 at 7:08 AM
finance.yahoo.com logoRXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15.0 Million
finance.yahoo.com - August 9 at 7:08 AM
americanbankingnews.com logoRXi Pharmaceuticals Corporation (NASDAQ:RXII) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - August 4 at 3:32 PM
prnewswire.com logoRXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing ... - PR Newswire (press release)
www.prnewswire.com - August 4 at 7:48 AM
prnewswire.com logoHow These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics - PR Newswire (press release)
www.prnewswire.com - August 4 at 7:48 AM
finance.yahoo.com logoRXi Pharmaceuticals to Webcast Second Quarter 2017 Financial Results on Thursday, August 10, 2017
finance.yahoo.com - August 4 at 7:48 AM
finance.yahoo.com logoRXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing Requirements
finance.yahoo.com - August 4 at 7:48 AM
americanbankingnews.com logo Brokerages Expect RXi Pharmaceuticals Corporation (RXII) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - July 30 at 7:42 AM
americanbankingnews.com logoZacks: RXi Pharmaceuticals Corporation (RXII) Given $6.50 Consensus Target Price by Analysts
www.americanbankingnews.com - July 13 at 8:29 AM
finance.yahoo.com logoRXi Pharmaceuticals Provides Update on Clinical Development Programs in New SNNLive Video Interview with StockNewsNow.com
finance.yahoo.com - July 6 at 8:38 AM
americanbankingnews.com logoZacks: Analysts Expect RXi Pharmaceuticals Corporation (NASDAQ:RXII) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - July 6 at 12:30 AM
americanbankingnews.com logoZacks: RXi Pharmaceuticals Corporation (RXII) Given $6.50 Average Price Target by Brokerages
www.americanbankingnews.com - June 27 at 7:42 AM
seekingalpha.com logoRXi Pharmaceuticals completes enrollment of Phase 1/2 clinical trial with RXI-109 for Retinal Scarring
seekingalpha.com - June 23 at 9:44 AM
streetinsider.com logoRXI Pharma (RXII) Completes Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring - StreetInsider.com
www.streetinsider.com - June 22 at 11:43 AM
finance.yahoo.com logoRXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring
finance.yahoo.com - June 22 at 11:43 AM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating RXi Pharmaceuticals Corporation for Potential ... - PR Newswire (press release)
www.prnewswire.com - June 16 at 9:32 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating RXi Pharmaceuticals Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 16 at 9:31 AM
americanbankingnews.com logoRXi Pharmaceuticals Corporation (RXII) Short Interest Update
www.americanbankingnews.com - June 14 at 7:14 AM
americanbankingnews.com logo RXi Pharmaceuticals Corporation (RXII) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - June 12 at 12:16 PM
finance.yahoo.com logoRXi Pharmaceuticals Announces the Initiation of its Consumer Testing Program with RXI-231
finance.yahoo.com - June 12 at 8:08 AM
americanbankingnews.com logo Analysts Anticipate RXi Pharmaceuticals Corp (RXII) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - June 10 at 12:28 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the Marcum MicroCap Conference
finance.yahoo.com - June 8 at 9:16 PM
finance.yahoo.com logoThe Life Sciences Report Examines RXi Pharmaceuticals Expanded Collaboration with Norwegian Cancer Firm and Gears Up for 2017 Milestones
finance.yahoo.com - June 8 at 9:16 PM
streetinsider.com logoRXI Pharma (RXII) Appoints Dr. Jonathan Freeman to the Board
www.streetinsider.com - June 8 at 3:20 AM
finance.yahoo.com logoRXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors
finance.yahoo.com - June 8 at 3:20 AM
seekingalpha.com logoRXi Pharmaceuticals (RXII) Presents At 3rd Annual Immuno-Oncology: BD&L and Investment Forum - Slideshow
seekingalpha.com - June 5 at 8:27 PM
americanbankingnews.com logo RXi Pharmaceuticals Corp (RXII) Receives Average Rating of "" from Brokerages
www.americanbankingnews.com - May 25 at 12:22 AM
bizjournals.com logoHow These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics
www.bizjournals.com - May 24 at 9:41 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum
finance.yahoo.com - May 23 at 9:32 AM

Social

Chart

RXi Pharmaceuticals Corporation (RXII) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff